Last reviewed · How we verify
polyethylene glycol powder
Polyethylene glycol powder, marketed by the Children's Hospital of Philadelphia, holds a position in the pharmaceutical market with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and the lack of immediate generic competition. However, the primary risk is the potential for increased competition post-patent expiry in 2028.
At a glance
| Generic name | polyethylene glycol powder |
|---|---|
| Sponsor | Children's Hospital of Philadelphia |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Pre-operative Polyethylene Glycol 3350 for Minimally Invasive Urogynecologic Surgery (PHASE4)
- Clinical Study of PEG Bowel Preparation in Appendectomy Patients
- Clinical Trial on Bowel Preparation Comparing Mannitol 100g to Plenvu Both in a Same Day Regimen (CLEARWAY) (PHASE3)
- The Associations Between Gut Length, Gut Microbiota and Food Assimilation
- Pre-packaged Low-residue Diet for Bowel Preparation in Patients With Inflammatory Bowel Disease (NA)
- Efficacy and Safety of Lubiprostone in the Treatment of Slow Transit Constipation (PHASE3)
- Study Assessing CLENPIQ as Bowel Preparation for Pediatric Colonoscopy (PHASE1, PHASE2)
- Comparing the Bowel Cleansing Efcacy of Picosulfate Sodium/ Citric Acid / Magnesium Oxide and Polyethylene Glycol: A Randomized Trial in Taiwan (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |